Most cancer deaths aren’t caused by the original tumor — they’re caused by what happens when cancer learns to move. Here’s the biology of metastasis, and why stopping it is one of medicine’s hardest problems.
Metastasis: How Cancer Escapes, Travels, and Builds New Colonies in Your Body
Most cancer deaths aren’t caused by the original tumor — they’re caused by what happens when cancer learns to move. Here’s the biology of metastasis, and why stopping it is one of medicine’s hardest problems.
🔬 Sources: Trends in Cell Biology / Cell Cancer Cell / Wiley MedComm Oncology 2025 / Frontiers in Pharmacology 2024–2025
Metastasis is the reason cancer kills
A tumor that stays exactly where it started is, in most cases, manageable. Surgery, radiation, local treatments — all of these work well against a contained tumor. The problem is that most cancers don’t stay contained. They metastasize: cancer cells break away from the primary tumor, enter the bloodstream or lymphatic system, travel to distant organs, and establish new tumors. This process is responsible for the vast majority of cancer-related deaths worldwide.
Metastasis is not a single event — it is a multi-step journey, and each step is a biological obstacle that cancer cells have to overcome. Research published in Wiley MedComm Oncology (2025) describes the full cascade: local invasion of surrounding tissue, entry into blood or lymphatic vessels (intravasation), survival in circulation, exit into a new tissue (extravasation), dormancy or immediate growth at the new site, and establishment of a secondary tumor with its own supporting microenvironment.
How cancer cells survive the bloodstream
The bloodstream is a hostile environment for a cancer cell. It’s turbulent, it’s patrolled by immune cells, and the mechanical forces of blood flow can destroy a fragile cell. Yet some cancer cells make it through. Research has shown that cells traveling in clusters — circulating tumor cell clusters — are significantly more likely to survive than individual cells, because clustering provides physical protection and suppresses the immune response.
Work published in Trends in Cell Biology (2025) shows that macrophages, neutrophils, and T cells play context-dependent roles in this process — sometimes attacking circulating tumor cells, and sometimes, depending on their phenotypic state, actually helping cancer cells adhere to new tissue and establish themselves. The immune system’s relationship with metastatic cancer is far more ambiguous than a simple attack-and-defend story.
🔬 Pre-metastatic niches: Cancer doesn’t just passively spread — it prepares the destination in advance. Primary tumors send out molecular signals that remodel distant organs before cancer cells even arrive, creating ‘pre-metastatic niches’ that are more hospitable to incoming tumor cells. This was confirmed in landmark studies reviewed in Cancer Cell.
Dormancy: cancer hiding in plain sight
One of the most unsettling aspects of metastasis is dormancy. Cancer cells can arrive at a distant organ, stop dividing, and enter a dormant state — essentially going silent for months, years, or even decades. During this period, they are nearly invisible to both the immune system and to standard cancer monitoring. Then something triggers them to reactivate, and a new tumor forms.
The biological mechanisms behind dormancy and reactivation are actively being studied. Current research (MedComm Oncology, 2025) points to interactions between dormant cells and their microenvironment — including changes in the extracellular matrix, shifts in immune surveillance, circadian rhythm disruptions, and gut microbiome changes — as key factors that determine whether a dormant cell stays quiet or wakes up. Understanding these triggers is critical for preventing late relapses in cancer survivors.
💡 Why this matters clinically: Many cancer relapses — sometimes called ‘late relapses’ — occur years or decades after successful treatment of the primary tumor. These are caused by dormant metastatic cells reactivating. Preventing dormancy reactivation is one of the major frontiers of cancer research.